Details of Host Protein-DME Interaction (HOSPPI)
| General Information of Drug-Metabolizing Enzyme (DME ID: DME0500) | |||||
|---|---|---|---|---|---|
| DME Name | Arginine carboxypeptidase (CPN1), Homo sapiens | DME Info | |||
| UniProt ID | |||||
| EC Number | EC: 3.4.17.3 (Click to Show/Hide the Complete EC Tree) | ||||
| Lineage | Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) | ||||
| Interactome | |||||
| Disease Specific Interactions between Host Protein and DME (HOSPPI) | |||||
|---|---|---|---|---|---|
| ICD Disease Classification 02 Neoplasms | |||||
| ICD-11: 2A00 Brain cancer | Click to Show/Hide the Full List of HOSPPI: 3 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Brain neuroblastoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 1.47E-08; delta-beta: -3.28E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CPN1 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can significantly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Multilayered rosettes embryonal tumour | Significant hypomethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 6.56E-31; delta-beta: -5.14E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CPN1 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can significantly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| DNA methyltransferase (DNMT) | Myxopapillary ependymoma | Significant hypomethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypomethylation p-value: 8.36E-26; delta-beta: -5.67E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hypo-methylate the CPN1 gene, which leads to a significantly increased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can significantly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2B90 Colorectal cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Colorectal cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 2.93E-10; delta-beta: 4.44E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CPN1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can significantly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
| The Methylation Level of Disease Section Compare with the Adjacent Tissue | Significant hypermethylation p-value: 7.69E-05; delta-beta: 3.94E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CPN1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can significantly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue adjacent to the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C12 Liver cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Liver cancer | Moderate hypomethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 1.06E-02; delta-beta: -2.02E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the CPN1 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can moderatly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
| The Methylation Level of Disease Section Compare with the Adjacent Tissue | Moderate hypomethylation p-value: 1.75E-09; delta-beta: -2.40E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the CPN1 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can moderatly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue adjacent to the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
DME methylation in tissue other than the diseased tissue of patients
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2C82 Prostate cancer | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Prostate cancer | Significant hypermethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 1.31E-08; delta-beta: 3.83E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CPN1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can significantly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2D50 Brain cancer metastasis | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Posterior fossa ependymoma | Moderate hypomethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 2.34E-39; delta-beta: -2.12E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the CPN1 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can moderatly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD-11: 2E06 Prostate cancer metastasis | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Prostate cancer metastasis | Significant hypermethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Significant hypermethylation p-value: 5.13E-04; delta-beta: 3.05E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to significantly hyper-methylate the CPN1 gene, which leads to a significantly decreased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can significantly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
| ICD Disease Classification 05 Endocrine/nutritional/metabolic diseases | |||||
| ICD-11: 5B81 Obesity | Click to Show/Hide the Full List of HOSPPI: 1 HOSPPI | ||||
| DNA methylation | |||||
| DNA methyltransferase (DNMT) | Obesity | Moderate hypomethylation | |||
| Interaction Name | DNMT-CPN1 interaction | ||||
| The Methylation Level of Disease Section Compare with the Healthy Individual Tissue | Moderate hypomethylation p-value: 3.46E-10; delta-beta: -2.33E-01 | ||||
| Description | DNA methyltransferase (DNMT) is reported to moderatly hypo-methylate the CPN1 gene, which leads to a moderatly increased expression of the drug-metabolizing enzyme Arginine carboxypeptidase. As a result, the interaction between DNMT and CPN1 can moderatly affect the drug-metabolizing process of Arginine carboxypeptidase. | ||||
|
DME methylation in the diseased tissue of patients
DME methylation in the normal tissue of healthy individuals
|
|||||
| Violin Diagram of DME Disease-specific Methylation Level |
|
Click to View the Clearer Original Diagram | |||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.